Dr Reddys' authorised generic injectable launch in US

News:Dr Reddy’s has launched authorised generic version of Par Pharma’s Vasostrict in strength of 20 units/ml (vasopressin injection) in the US. Estimated market size for Vasostrict in US is ~ US$878.5 million (MAT December 2021, IQVIA).

Views:Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock. This authorised generic launch is in the backdrop of the US launch of ANDA for vasopressin by Eagle pharma in January, 2022 with 180 days of exclusivity. Dr Reddy’s is likely to benefit through ramping up the market share in this high value product with limited competition and we expect Dr Reddy’s US business to grow at a CAGR of 7.5% in FY21-24E to Rs.8750 crore.

Impact: Positive